Clinical Trial 9735

Stamford, CT 06902

Study Summary:

FAR-131: A Study for women with ovarian cancer recurrence

About the study

This clinical research study is investigating whether the investigational drug MORAb-003 (farletuzumab) is safe and effective when given in combination with carboplatin and taxane for women who have platinum-sensitive epithelial ovarian cancer that relapsed between 6 and 24 months after first-line treatment with a platinum-containing chemotherapy regimen.

About the study drug

Farletuzumab is a monoclonal antibody that targets a protein (located on the cell surface) that is believed to be important for cancer cell growth and survival. This protein is present in large quantities in ovarian cancer cells but not in normal cells. At this time, farletuzumab is available only to ovarian cancer patients in clinical research studies such as FAR-131.

Who can participate?

You may be eligible if you:

  • Are a female >18 years of age
  • Have been diagnosed with ovarian cancer
  • Relapsed within > 6 and < 24 months from completion of first-line platinum and taxane chemotherapy
  • Are a candidate for repeat carboplatin and taxane therapy
What does the study involve?

Eligible study participants will be asked to:
  • Provide informed consent
  • Attend study visits
  • Receive the study drugs by infusion
  • Undergo study-related physical exams
  • Speak with the study staff about your health and wellbeing
Participants will receive Farletuzumab or placebo in combination with standard of care medications, carboplatin and taxane. vBulletin statistics

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.